Zimmer Biomet posted second quarter revenue growth, and the company has four pillars of focus for its hip and knee businesses, CEO Bryan Hanson said in an Aug. 1 earning call.
The company is focusing on the Rosa robotics platform combined with the Persona cementless knee, revising the Persona knee portfolio, the Persona iQ smart knee and shifting away from the Zimmer Biomet legacy knee products, Mr. Hanson said, as transcribed by Seeking Alpha.
For hip products, the company is focusing on Rosa robotics and Hip Insight, the Avenir Complete system, the upcoming HAMR automated impaction system and a triple taper stem device.
Mr. Hanson said Zimmer Biomet has 40 product launches in the pipeline from 2023 through 2025.
"This portfolio shift that we're seeing and the team's execution capabilities are clear signs that our [Zimmer Biomet] transformation has taken hold," he said. "But I can tell you right now that we're not going to stop there."